PAC INFECTO-1 C3
Contenido
REFERENCIAS

  1. Finland M, Garner, Wilcox C, Sabath LD. Susceptibility of Pneumococci and Haemophilus influenzae to antibacterial agents. Antimicrob Agents Chemother 1976; 9: 274-87.

  2. Sutter VL, Finegold SM. Susceptibility of anaerobic bacteria to 23 antimicrobial agents. Antimicrob Agents Chemother 1976; 10: 736-52.

  3. Coppens L, Klastersky J. Comparative study of anti-pseudomonas activity of azlocillin, mezlocillin, piperacillin, and ticarcillin, alone and in combination with an aminoglicoside. Antimicrob Agents Chemother 1979; 15: 396-99.

  4. Tomasz A. From Penicillin-binding proteins to the lisis and death of bacteria: a 1979 view. Rev Infect Dis 1979; 33: 113-37.

  5. Tomasz A. Penicillin-binding proteins and the antibacterial effectiveness of the beta-lactam antibiotics. Rev Infect Dis 1986; 8(Suppl 3): S270-78.

  6. Morfín-Otero R, Rodríguez-Noriega E. Enterobacterias con Betalactamasas de espectro extendido: su importancia como patógenos nosocomiales. Enf Infecci Microbiol 1999; 19: 116-32.

  7. Yoshimura F, Nikaido H. Diffusion of b-lactam antibiotics through the porin channels of Escherichia coli K-12. Antimicrob Agents Chemother 1985, 27: 84-92.

  8. Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: Genetics and mechanisms of resistance. Antimicrob Agents Chemother 1989; 33: 991-94.

  9. Young EJ, Weingarten NM, Baughn RE, Duncan WC. Studies on the pathogenesis of the Jarisch-Herxheimer reaction. J Infect Dis 1982; 146: 600-15.

  10. John CC. Treatment failure with use of third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis 1994; 18: 188-93.

  11. Sloas MM, Barrett FF, Chesney PJ, English BK, Hill BC, Tenover FC, Leggiadro RJ. Cephalosporin treatment failure in penicillin and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1992; 11: 662-66.

  12. Friedland IR, Paris M, Ehrett S, Hickey S, Olsen K, McCraken GH. Evaluation of antimicrobial regimens for treatment of experimental penicillin-cephalosporin resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993; 37: 1630-36.

  13. Mason EO, Kaplan SL, Lamberth LB, Tillman J. Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children´s hospital and in vitro susceptibilities to antibiotics of potential therapeutic use. Antimicrob Agents Chemother 1992; 36: 1703-07.

  14. Bluestone CD. Current therapy for otitis media and criteria for evaluation of new antimicrobial agents. Clin Infect Dis 1992; 14(Suppl 2): S197-S203.

  15. Krause PJ, Owen NJ, Nightingale CH, Klimek JJ, Lehmann WB, Quintiliani R. Penetration of amoxicilina, cefaclor, erithromycin-sulfixazole and trimethoprim-sulfamethoxazole in the middle ear fluid of patients with chronic serous otitis media. J Infect Dis 1982; 145: 815-21.

  16. Blummer JL, McLinn SE, Deabale CA, Kafetzis DA, Perrotta RJ, Salgado O. Multinational multicenter controlled trial comparing ceftibuten with cefaclor for the treatment of acute otitis media. Pediatr Infect Dis J 1995; 14: S115-120.

  17. Pichichero ME, Margolis PA. A comparison of cephalosporins and penicillins in the treatment of group A b-haemolytic streptococcal pharyngitis: A meta-analysis supporting the concept of microbial co-pathogenialy. Pediatr Infect Dis J 1991; 10: 275-81.

  18. Bansal MB, Chuah SK, Thadepalli H. In vitro activity and in vivo evaluation of ticarcillin plus clavulanic acid against aerobic and anaerobic bacteria. Am J Med 1985; 79(Suppl 5B): 33-8.

  19. Labia R, Morand A, Lelievre V, Mattioni D, Kazmierczak A. Sulbactam: biochemical factors involved in its synergy with ampicillin. Rev Infect Dis 1986; 8(Suppl 5): S496-502.

  20. Bush K. b-lactamase inhibitors. Clin Microbiol Rev 1988; 1: 109-23.

  21. Zhou XY, Bordon F, Sirot D, Kitzis MD, Gutmann L. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives of an OXA-1 b-lactamase conferring resistance to b-lactamase inhibitors. Antimicrob Agents Chemother 1994; 38: 1085-89.

  22. Brismar B, Malmborg AS, Tunevall G, Wretlind B, Bergman L, Mentzig LO, Nystrom PO, Kihlstrom E, Backstrand B, Skau T, Kasholm-Tengve B, Sjoberg L, Olsson-Liljequist B, Tally FP, Gatenbeck L, Eklund AE, Nord CE. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.Antimicrob Agents Chemother 1992; 36: 2766-73.

  23. Pastopek JG, Aldridge KE, Cunningham GL, Garo S, Graffeo S, Mcneely GS, Tan JS. Comparison of ticarcillin plus clavulanic acid with cefoxitin in the treatment of female pelvic infection. Am J Med 1985; 79: 161-63.

  24. Davis JE. Resistance to aminoglicosides: mechanisms and frequency. Rev Infect Dis 1983; 5: S261-66.

  25. Matsunaga K, Yamaki H, Nishimura T, Tanaka N. Inhibition of DNA replication initiation by aminoglycoside antibiotics. Antimicrob Agents Chemother 1986; 30: 468-74.

  26. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglicoside-modifying enzymes. Microbiol Rev 1993; 57: 138-63.

  27. Miller GH, Sabatelli FJ, Hare RS, Glypczynsky Y, Mackey P, Shlaes D, Shimizu K, Shaw KJ. Aminoglycoside resistance study groups. The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns. Clin Infect Dis 1997; 24(Suppl 1): S46-62.

  28. Fausti SA, Henry JA, Sctheffer HI, Olson DJ, Frey RH, McDonald WJ. High-frecuency audiometric monitoring for early detection of aminoglycoside toxicity. J Infect Dis 1992; 165: 1026-32.

  29. Hutchin T, Cortopassi G. Proposed molecular and celullar mechanism for aminoglycoside toxicity. Antimicrob Agents Chemother 1994; 38: 2517-20.

  30. Lerner SA, Schmitt BA, Seligsohn R, Matz GJ. Comparative study of ototoxicity and neprotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med 1986; 80(Suppl 6B): 98-104.

  31. Wolfson JS, Hooper DC. The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985; 28: 581-86.

  32. Yoshida T, Muratani T, Iyobe S, Mitsuhashi S. Mechanisms of high level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994; 38: 1466-69.

  33. Li X-Z, Livermore DM, Nikado H. Role of efflux pump(s) in intrinsec resistance to Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother 1994; 38: 1732-41.

  34. Arcieri GM, Becker N, Esposito B, Griffith E, Heyd A, Neumann C, O´Brien B, Schacht P. Safety of intravenous cirprofloxacin. Am J Med 1989; 87(5A): 92S-7.

  35. Hooton TM, Latham RH, Wong ES, Johnson C, Roberts PL, Stamm WE. Ofloxacin versus trimethoprim-sulfamethoxazole for treatment of acute cystitis. Antimicrob Agents Chemother 1989; 33: 1308-12.

  36. Weidner W, Schiefer HG, Dalhoff A. Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. Am J Med 1987; 82(Suppl 4A): 280-83.

  37. DuPont HL, Ericsson CD, Mathewson JJ, DuPont MW. Five versus three days of ofloxacin therapy for traveler´s diarrhea: a placebo-controlled study. Antimicrob Agents Chemother 1992; 36: 87-91.

  38. Gentry LO, Ramirez-Ronda CH, Rodríguez-Noriega E, Thadepalli H, del Rosal PL, Ramírez C. Oral ciprofloxacin vs. parenteral cefotaxime in the treatment of difficult skin and skin structure infections: a multicenter trial. Arch Intern Med 1989; 149: 2579-2583.

  39. Gentry LO, Rodríguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother 1990; 34: 40-3.

  40. Fukasawa M, Sumita Y, Harabe ET, Tanio T, Nouda H, Kohzuki T, Okuda T, Matsumura H, Sunagawa M. Stability of meropenem and effect of 1 Beta-methil substitution on its stability in the presence of renal deydropeptidase I. Antimicrob Agents Chemother 1992; 36: 1577-79.

  41. Jorgensen JH, Maher LA, Howell AW. Activity of a new carbapenem antibiotic, meropenem, against Haemophilus influenzae stains with beta-lactamase and non-enzyme mediated resistance to ampicillin. Antimicrob Agents Chemother 1991, 35: 600-2.

  42. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibilities of 394 Bacteroides fragilis, non B group Bacteroides species, and Fusobacterium species to newer antimicrobial agents. Antimicrob Agents Chemother 1991; 35: 1214-18.

  43. Cuchural GJ, Malamy MH, Tally FP. b-lactamase-mediated imipenem resistance in Bacteroides fragilis. Antimicrob Agents Chemother 1993; 32: 695-703.

  44. Calandra GB, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisponing to seizures in seriously ill infected patients receiving antibiotics: Experience with imipenem/cilastatin. Am J Med 1988; 84: 911-18.

  45. Barry A, Thornsberry C, Jones R, Gavan T. Aztreonam: Antibacterial activity, b-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests. Rev Infect Dis 1985; 7(Suppl 4): S594-S604.

  46. Nolen T, Phillips H, Hall H. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli. Rev Infect Dis 1985; 7(Suppl 4): S666-68.

  47. Williams R, Hotechkin D. Aztreonam plus clindamycin versus tobramycin plus clindamicin in the treatment of abdominal infections. Rev Infect Dis 1991; 13(Suppl 7): S629-33.

  48. Swlly B, Henry S. Clinical experience with aztreonam in the treatment of gram-negative bacteremia. Rev Infect Dis 1985; 7(Suppl 4): S789-93.

  49. Menninger JR. Functional consequences of binding macrolids to ribosomes. J Antimicrob Chemother 1985; 16(Suppl A): 23-24.

  50. Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother 1993; 31(Suppl C): 1-9.

  51. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosinamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991; 35: 1267-72.

  52. O´hara K, Yamamoto K. Reaction of chlarithromycin with macrolide inactivating enzymes from highly resistant Escherichia coli. Antimicrob Agents Chemother 1996; 40: 1036-38.

  53. Wondrack L, Massa M, Yand BV, Sutcliffe J. Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. Antimicrob Agents Chemother 1996; 40: 992-98.

  54. Carson JL, Strom BL, Duff A. Acute liver disease associated with erythromycin, sulfonamides, and tetracyclines. Ann Intern Med 1993; 119: 576-583.

  55. Bohnen JM, Solomkin JS, Dellinger EP, Bjornson HS, Page CP. Guidelines for clinical care: Anti-infective agents for intraabdominal infection a surgical society policy statement. Arch Surg 1992; 127: 83-9.

  56. Milatovic D, Braveny IN, Verhoef J. Clindamycin enhances opsonization of Staphylococcus aureus. Antimicrob Agents Chemother 1983; 24: 413-17.

  57. Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production and host response. Clin Infect Dis 1995; 20(Suppl 2): S154-57.

  58. Sanders CC, Sanders WE JR, Georing RV. Influence of clindamycin on depression of b-lactamases in Enterobacter spp. and Pseudomonas aeruginosa. Antimicrob Agents Chemother 1983; 24: 48-53.

  59. Klastersky J, Husson M. Bactericidal activity of the combination of gentamicin with clindamycin or chloramphenicol against species of Escherichia coli and Bacteroides fragilis. Antimicrob Agents Chemother 1977; 12: 135-38.

  60. Corey WA, Doebbeling BN, DeJong KJ, Britigan BE. Metronidazole-induced acute pancreatitis. Rev Infect Dis 1991; 13: 1213-15.

  61. Leclerq R, Dutka-Malen S, Brisson-Noel A, et al. Resistance of enterococi to aminoglycosides and glycopeptides. Clin Infect Dis 1992; 15: 495-501.

  62. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: Reappraisal of their clinical valve. Clin Infect Dis 1994; 18: 533-43.

  63. Cook DW, Farrar WE Jr. Vancomycin revisited. Ann Intern Med 1978; 88: 813-18.

  64. O´Sullivan TL, Riffing MJ, Lamp KC, Warbasse LH, Rybak MJ. Prospective evaluation of red man syndrome in patients receiving vancomycin. J Infect Dis 1993; 168: 773-76.

  65. bibler MR, Frame PT, Hagler DN, Bode RB, Stanek JL, Thamlikiktul V, Harris JE, Haregewoin A Bullock WE Jr. Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections. Antimicrob Agents Chemother 1987;31: 207-12.

  66. Rahal JJ Jr, Simerkoff MS. Bactericidal and bacteriostatic action of chloramphenicol against meningeal pathogens. Antimicrob Agents Chemother 1979; 16: 13-18.

  67. Murray BE. Resistance of Shigella, Salmonella, and other selected enteric pathogens to antimicrobial agents. Rev Infect Dis 1986; 8(Suppl 2): S172-81.

  68. Sutherland JM. Fatal cardiovascular collapse of infants receiving large amount of chloramphenicol. Am J Dis Child. 1959; 97: 761.

  69. Yunis AA. Chloramphenicol toxicity: 25 years of research. Am J Med 1989; 87(3N): 44.

  70. Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin Microbiol Rev 1992; 5: 387-99.

  71. Schultz JC, Adamsden JS Jr, Workman WW. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 1963; 269: 999-1004.

  72. Steere AC. Lyme disease, N Engl J Med 1989; 321: 586-96.

  73. Lwwin C, Doherty C, Govan J. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramfenicol, cotrimoxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother 1993; 37: 123-25.

  74. Bastian I, Bowden FJ. Amplification of Klebsiella-like sequences from biopsy samples from patients with donovanosis. Clin Infect Dis 1996; 23: 1228-30.

  75. Parenti DM, Snydman DR. Capnocytophaga species: infections in nonimmunocompromised and immunocompromised hosts. J Infect Dis 1985; 151: 140-47.

  76. Ponte R, Jenkins SG. Fatal Chromobacterium violaceum infections associated with exposure to stagnant waters. Pediatr Infect Dis J 1992; 11: 583-86.

  77. Reboli AC, Farrar WE. Erysepelotrix rusopathiae: an occupational pathogen. Clin Microbiol Rev. 1989; 2: 354-59.

  78. Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: Review of the literature. Clin Infect Dis 1994; 19: 42-47.

  79. Evans ME, Gregory DW, Schaffner McGee ZA. Tularemia: a 30 year experience with 88 cases. Medicine (Baltimore) 1985; 64: 251-69.

  80. Martin DH, Sargent SJ, Wendel GD Jr, McCormack, WM, Spier NA, Johnson RB. Comparison of azithromycin and ceftriaxone for the treatment of chancroid. Clin Infect Dis 1995; 21: 409-14.

  81. Fraser DW, Tsai T, Ornstein W, et al. Legionnaires disease: description of an epidemic of pneumonia. N Engl J Med 1977; 297: 1189-97.

  82. Farr RW. Leptospirosis. Clin Infect Dis 1995; 21: 1-6.

  83. Charpentier E, Gerbaud G, Jacquet C, Rocourt J, Courvalin P. Incidence of antibiotic resistance in Listeria species. J Infect Dis 1995; 172: 277-81.

  84. Goldstein EJC. Bite wounds and infections. Clin Infect Dis 1992; 14: 633-40.

  85. Elting LS, Bodey GP. Septicemia due to Xanthomonas species and non-aeruginosa pseudomonas species. Increasing incidence of catheter related infections. Medicine 1990; 69: 296-306.

  86. Bisset J, Powers LC, Abbott SL, Janda JM. Epidemiologic investigations of Yersinia enterocolitica and related species: Sources, frequency, and serogroup distribution. J Clin Microbiol 1990; 28: 910-12.
Contenido
Copyright © 2005 Dr. Scope. Derechos Reservados.
Diseño y Programación: Educación Médica Contínua